FDA Approves TALVEY — Janssen Biotech, Inc.

(Janssen) announced Wednesday the FDA approval of Talvey (talquetamab), a novel antibody directed against both GPRC5D and BCMA, which targets multiple myeloma patients with ineligible or unsustainable prior treatment options. This approval positions Janssen to enter a high-growth niche in the bispecific antibody market, intensifying the strategic race against rival therapies to capture sales from patients progressing on standard-of-care regimens.